Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO

Alexander S. Streng¹,∗ Thijs S.R. Delnoij²,3,∗ Mark M.G. Mulder² Jan Willem E.M. Sels²,3
Rick J.H. Wetzels¹ Paul W.M. Verhezen¹ Renske H. Olie⁴,⁵ Jeroen P. Kooman⁶
Sander M.J. van Kuijk⁷,⁸ Lloyd Brandts⁷ Hugo ten Cate⁴,⁵ Roberto Lorusso⁵,⁹
Iwan C.C. van der Horst² Bas C.T. van Busse²,⁸ Yvonne M.C. Henskens¹,⁵

¹ Central Diagnostic Laboratory, Maastricht University Medical Centre, Maastricht, the Netherlands
² Intensive Care Unit, Maastricht University Medical Centre, Maastricht, the Netherlands
³ Cardiovascular Centre, Maastricht University Medical Centre, Maastricht, the Netherlands
⁴ Department of Vascular Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands
⁵ Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands
⁶ Department of Clinical Nephrology, Maastricht University Medical Centre, Maastricht, the Netherlands
⁷ Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, the Netherlands
⁸ Care and Public Health Research Institute, Maastricht University Medical Centre, Maastricht, the Netherlands
⁹ Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, the Netherlands

TH Open 2020;4:e365–e375.

Address for correspondence Alexander S. Streng, PhD, Central Diagnostic Laboratory, Maastricht University Medical Centre, P. Debyelaan 25, 6229HX Maastricht, the Netherlands (e-mail: sander.streng@mumc.nl).

Keywords
► COVID-19
► heparin resistance
► heparin therapeutic range
► aPTT
► anti-Xa

Abstract
Objective Severe cases of coronavirus disease 2019 (COVID-19) can require continuous renal replacement therapy (CRRT) and/or extracorporeal membrane oxygenation (ECMO). Unfractionated heparin (UFH) to prevent circuit clotting is mandatory but monitoring is complicated by (pseudo)-heparin resistance. In this observational study, we compared two different activated partial thromboplastin time (aPTT) assays and a chromogenic anti-Xa assay in COVID-19 patients on CRRT or ECMO in relation to their UFH dosages and acute phase reactants.

Materials and Methods The aPTT (optical [aPTT-CS] and/or mechanical [aPTT-STA] clot detection methods were used), anti-Xa, factor VIII (FVIII), antithrombin III (ATIII), and fibrinogen were measured in 342 samples from 7 COVID-19 patients on CRRT or ECMO during their UFH treatment. Dosage of UFH was primarily based on the aPTT-CS with a heparin therapeutic range (HTR) of 50–80s. Associations between different variables were made using linear regression and Bland–Altman analysis.

Results Dosage of UFH was above 35,000IU/24 hours in all patients. aPTT-CS and aPTT-STA were predominantly within the HTR. Anti-Xa was predominantly above the

* Equal contribution.
Introduction

In patients with severe cases of coronavirus disease 2019 (COVID-19) admitted to the intensive care unit (ICU), extracorporeal devices such as extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT) may be temporarily required to support organ function. Use of ECMO and CRRT results in excessive stimulation of the coagulation system due to blood contact with a variety of nonphysiological surfaces, potentially leading to gradual or sudden thrombosis and the accumulation of thrombi throughout the extracorporeal system, which can result in interruption of such supportive treatments. Therefore, adequate anticoagulation is required during these procedures, for which unfractionated heparin (UFH) is commonly used. Furthermore, a prothrombotic condition, in association with a demonstrated hyper-inflammatory state, has been demonstrated in COVID-19 patients, thereby prompting the adoption of higher anticoagulation treatment.

Monitoring of adequate UFH dosage is essential to maintain the delicate balance between bleeding and thrombosis. The activated partial thromboplastin time (aPTT) reflects the intrinsic coagulation pathway and is the most commonly used test to monitor UFH. Activated clotting time and anti-Xa activity tests are also performed. When using the anti-Xa test, practical guidelines suggest a heparin therapeutic range (HTR) of 0.3 to 0.7 IU/mL. However, those same guidelines are less specific about which HTR to use when monitoring UFH with the aPTT. An aPTT ratio of 1.5 to 2.5 (aPTT of the patient/aPTT of pooled reference plasma) was suggested in a 1972 study and gained wide acceptance. However, other authors have suggested that an aPTT ratio of 2.0 to 3.5 may be more suitable. Because large differences exist between different reagents and platforms, each laboratory should ideally determine the aPTT target range based on a corresponding anti-Xa activity of 0.3 to 0.7 IU/mL. In our laboratory, UFH is monitored using the aPTT with a HTR of 50 to 80 s, based on an aPTT ratio of 1.5 to 2.5. We utilize two different instruments for the aPTT: the Sysmex CS2100i (optical clot detection and the default instrument) and the Stago STA-R Max 2 (mechanical clot detection).

Another frequently encountered challenge in heparin monitoring is heparin resistance. Heparin resistance can be defined as the requirement of more than 35,000 units of UFH in 24 hours to reach therapeutic aPTT levels and is classically caused by antithrombin III (ATIII) deficiency. ATIII-independent forms of heparin resistance (also called “apparent,” or “pseudo” heparin resistance) occur as well, possibly caused by high concentrations of FVIII, fibrinogen, or platelets. Apparent heparin resistance is assumed to be an in vitro effect only, but the mechanisms and clinical meaning of this phenomenon are not fully discerned and may not apply to COVID-19 patients. Nevertheless, international guidelines recommend the use of anti-Xa testing with a HTR of 0.3 to 0.7 IU/mL instead of the aPTT to manage patients with heparin resistance.

COVID-19 coagulopathy is characterized by high FVIII and fibrinogen concentrations and predominantly normal ATIII levels. During the COVID-19 epidemic, we were confronted with several cases in which the usually effective dose of UFH was insufficient to reach the HTR (defined as an aPTT of 50–80 seconds in our hospital). This prompted us to begin a longitudinal assessment of the aPTT, FVIII, fibrinogen, ATIII, and anti-Xa activity in seven patients diagnosed with COVID-19 on CRRT or ECMO and treated with UFH. The clinical dilemma is that neither the aPTT nor the anti-Xa assays have been assessed for their validity to monitor UFH in the setting of profound thrombo-inflammation such as in COVID-19, where heparin resistance is rather frequently observed. The aim of this explorative study was to compare a mechanical and optical aPTT assay with one another and with the anti-Xa to gain more insight in the causes of heparin resistance and in monitoring strategies for UFH in COVID-19 patients on ECMO or CRRT.

Materials and Methods

Patients and Study Design

The Maastricht Intensive Care COVID (MaastrICCht) cohort is a prospective cohort study that is conducted in patients admitted to the ICU of the Maastricht University Medical Center (Maastricht UMC+). It included 81 patients who had to be intubated and mechanically ventilated and needed to have signs and symptoms of a viral infection including a polymere chain reaction positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and/or a chest CT scan scored positive based on a CORADS-score of 4 to 5 by a radiologist. Patients were admitted via our emergency
department, via non-ICU wards and by transportation from other ICUs either for tertiary care referral, such as ECMO, or due to lack of bed availability in the regional hospitals.

As we observed clinically high UFH dosages with low corresponding aPTT result in mechanically ventilated patients with extracorporeal support, we conducted a comprehensive longitudinal study on coagulation using a subcohort of seven consecutive patients receiving therapeutic dosages of UFH for either CRRT or ECMO within a study period of 1 month. ECMO consisted of venovenous extracorporeal membrane oxygenation (VV-ECMO) with the PLS and Cardiohelp HLS system (Maquet Cardiopulmonary, Rastatt, Germany). Indications for VV-ECMO support were a P/F-ratio < 80 mm Hg despite prone positioning and high PEEP (> 15 cmH2O), ventilator support <6 days, age <70 years, mono-organ failure, and no severe comorbidities. CRRT was initiated in case of acute kidney insufficiency (AKI) KDIGO stage 3 and consisted of continuous venovenous hemodiafiltration (CVVHD) using the multiFiltrate system (Fresenius Medical Care, Bad Homburg, Germany).

The local institutional review board (Medisch Ethische Toetsingscommissie (METc) 2020–1565/300523) of the Maastricht UMC+ waived consent and approved the MaastrICht cohort study, in accordance with the Declaration of Helsinki. For the present subcohort, patient families were contacted and provided oral consent.

**Blood Collection, Preparation, and Storage**

Atrial blood was routinely collected using 4.0 mL BD (Becton Dickinson, Plymouth, United Kingdom) 7.2 mg K2 EDTA, 2.7 mL BD 3.2% citrate, and 5.0 mL BD serum Vacutainer vacuum tubes. Platelet measurements were performed within 2 hours of blood collection. Platelet free plasma (PFP) was obtained by centrifugation of citrated blood at 2000 rpm for 10 minutes and subsequently at 10 000 g for 10 minutes at 18°C. PFP was prepared and frozen (-80°C) within 4 hours of blood collection. Routine hematology tests (aPTT, fibrinogen, D-dimers, ATIII) were performed within 2 hours of blood collection. aPTT measurements on the STA-R Max2 intended for assay comparison, as well as Anti-Xa and FVIII were performed in stored PFP (-80°C), thawed for 10 minutes at 37°C.

**Laboratory Measurements**

The aPTT (Dade Actin FSL; Siemens, Marburg, Germany), PT (Dade Innovin; Siemens), fibrinogen level (Clauss method, Dade Thrombin Reagent; Siemens), FVIII activity (Dade Actine FS and FVIII deficient plasma; Siemens), D-dimer (INNOVANCE D-dimer; Siemens), antithrombin (INNOVANCE; Siemens), and anti-Xa (Biophen Heparin LRT; Hyphen Biomed, Neuville-Sur-Souse, France) were measured on a Sysmex CS2100i (Sysmex Corporation, Kobe, Hyogo, Japan) hemostasis analyzer. Samples for the anti-Xa test were first diluted 2x with pooled reference plasma containing ~100% ATIII and the anti-Xa activity was subsequently determined using specific calibration lines for UFH (aXa-UFH) (Biophen UFH Calibrator; Hyphen Biomed) or low-molecular-weight heparin (LMWH) (aXa-LMWH) (Biophen Heparine Calibrator; Hyphen Biomed). The aPTT (Cephascreen; Stago, Paris, France) was also performed on a STA-R Max2 analyzer (Stago). Thrombocyte count was determined using a Sysmex XN-9000 analyzer (Sysmex). C-reactive protein (CRP, third generation, Roche Diagnostics, Basel, Switzerland) and ferritin (Elecsys ferritin, Roche) were performed on the COBAS8000 by Roche Diagnostics.

**Statistical Analysis**

The seven patients of this substudy were compared with the 81 patients of the MaastrICht cohort. Means ± standard deviation, median (IQR) or percentages are presented and compared using independent Student’s t-test, or chi-squared test as appropriate, with a p-value of 0.05 being considered statistically significant.

Associations between the different variables were made using simple linear regression and Bland–Altman analysis.

**Results**

- **Table 1** shows that there were no differences between the seven patients and the entire MaastrICht cohort, except that they were younger, had a relatively higher prevalence of ECMO and CRRT, and a lower Simplified Acute Physiology Score II. All included patients experienced heparin resistance.

The actual heparin dose (in IU/h) and bolus injections (in IU) administered to each patient are depicted in **Fig. 1**, together with the aPTT (left panels) and the anti-Xa activity (right panels). It typically takes 1 to 2 days of an increasing dose of heparin, often combined with several bolus injections, to reach the HTR of 50 to 80 seconds. After reaching the HTR, patients 3, 4, and 6 then required a relatively constant dose of heparin to maintain a stable aPTT. In patient 1, the heparin dose necessary to keep the aPTT from falling, required repeated dose increases (up to a maximum of 4,000 IU/mL). By default, the aPTT was measured on the Sysmex CS2100i, which utilizes optical clot detection. Due to interferences in the optical method (so-called early-reaction errors, or biphasic waveforms, for example caused by hemolysis or turbidity), the platform used for aPTT measurement was changed to the Stago STA-R Max 2 (which utilizes mechanical clot detection) halfway during treatment in patients 2 and 5. This change in method was accompanied by an increase in the aPTT and a gradual decrease in the UFH dosage. The aPTT of patient 7 was measured on the STA-R Max 2 since the beginning of her UFH treatment. In the majority of samples, the anti-Xa activity is consistently higher than the target HTR of 0.3 to 0.7 IU/mL, but is in most cases below the therapeutic threshold of 1.0 IU/mL. - **Table 2** shows additional clinical characteristics for each individual patient.

**Comparison of Different Anti-Xa and aPTT Assays**

Next, the agreement and correlation between different anti-Xa calibrators and aPTT methods were analyzed. - **Fig. 2A** shows the correlation between aXa-LMWH and aXa-UFH in 37 samples (r² = 0.99). A factor difference of 1.55 exists between the two variables: aXa-UFH = 1.55 × aXa-LMWH. Because of the near-perfect correlation, the LMWH calibration line was used throughout this study after conversion of the values to aXa-UFH by multiplication of aXa-LMWH with 1.55. Bland–Altman analysis shows an average bias of 37.2% (– **Fig. 2B**). The relative bias is significantly less below 0.4 IU/mL.
**Table 1** Comparison of the patient characteristics between the Maastricht Intensive Care COVID cohort (MaastrICCht) and the seven individual cases of the present subcohort

| Variables                        | MaastrICCht–Subcohort (n = 74) | Subcohort (n = 7) | P-Value |
|----------------------------------|---------------------------------|-------------------|---------|
| **General**                      |                                 |                   |         |
| Age (y), mean (SD)               | 65.7 (11.0)                     | 52.0 (17.9)       | 0.004   |
| Gender (male), n (%)             | 58 (78.4)                       | 5 (71.4)          | 0.677   |
| Height (cm), mean (SD)           | 175.4 (8.6)                     | 174.9 (10.4)      | 0.869   |
| Weight (kg), mean (SD)           | 84.8 (13.5)                     | 83.1 (9.5)        | 0.747   |
| Body mass index (kg/m²), mean (SD) | 27.6 (4.3)                     | 27.2 (2.5)        | 0.796   |
| **Chronic health conditions**    |                                 |                   |         |
| Hypertension (yes), n (%)        | 26 (35.1)                       | 2 (28.6)          | 1.000   |
| Dyslipidemia (yes), n (%)        | 15 (20.3)                       | 1 (14.3)          | 1.000   |
| Diabetes Mellitus (yes), n (%)   | 13 (17.6)                       | 0 (0)             | 0.591   |
| Chronic kidney disease (yes), n (%) | 1 (1.4)                        | 1 (14.3)          | 0.166   |
| Malignancy (yes), n (%)          | 6 (8.1)                         | 0 (0)             | 1.000   |
| Liver disease (yes), n (%)       | 1 (1.4)                         | 0 (0)             | 1.000   |
| Chronic lung disease (yes), n (%) | 8 (10.8)                       | 0 (0)             | 1.000   |
| Myocardial infarction (yes), n (%) | 3 (4.1)                         | 0 (0)             | 1.000   |
| Congestive heart failure (yes), n (%) | 1 (1.4)                        | 0 (0)             | 1.000   |
| Peripheral vascular disease (yes), n (%) | 2 (2.7)                      | 1 (14.3)          | 0.240   |
| CVA of TIA (yes), n (%)          | 10 (13.5)                       | 0 (0)             | 0.588   |
| Dementia (yes), n (%)            | 0 (0)                           | 0 (0)             | NA      |
| Connective tissue disease (yes), n (%) | 0 (0)                          | 0 (0)             | NA      |
| Peptic ulcer disease (yes), n (%) | 1 (1.4)                         | 0 (0)             | 1.000   |
| Immunosuppression (yes), n (%)   | 2 (2.7)                         | 0 (0)             | 1.000   |
| AIDS (yes), n (%)                | 0 (0)                           | 0 (0)             | NA      |
| **Disease severity algorithms**  |                                 |                   |         |
| APACHE II, mean (SD)             | 16.0 (6.0)                      | 15.7 (4.4)        | 0.916   |
| SAPS II, mean (SD)               | 41.3 (13.9)                     | 30.1 (8.5)        | 0.041   |
| **Advanced therapy**            |                                 |                   |         |
| ECMO (yes), n (%)                | 5 (6.8)                         | 3 (42.9)          | 0.019   |
| CRRT (yes), n (%)                | 11 (14.9)                       | 4 (57.1)          | 0.020   |
| Mechanical ventilation (yes), n (%) | 74 (100)                       | 7 (100)           | NA      |
| Heparin therapy (yes), n (%)     | 17 (23.0)                       | 7 (100)           | <0.01   |
| Heparin resistance (yes), n (%)  | 10 (13.5)                       | 7 (100)           | <0.01   |

Abbreviations: APACHE II, Acute Physiology And Chronic Health Evaluation II; CRRT, continuous renal replacement therapy; MaastrICCht, Maastricht Intensive Care COVID cohort; NA, not applicable; SAPS II, Simplified Acute Physiology; Score II, ECMO, extracorporeal membrane oxygenation; SD, standard deviation.

*The subcohort is part of the Maastricht Intensive Care COVID cohort.

<sup>b</sup>Independent sample t-test for equal variances.

<sup>c</sup>Comparing groups by the Fisher’s exact test.

<sup>d</sup>Defined by >35.000 U/24 hours.

---

**Fig. 2C** shows the correlation between the optical aPTT (aPTT-CS) and the mechanical aPTT (aPTT-STA) ($r^2 = 0.68$). The aPTT measured with the mechanical method is consistently higher than the aPTT measured with the optical method: aPTT-STA = 1.4 * aPTT-CS + 6. Bland–Altman analysis shows an average bias of 39.3% with an even spread across the entire measuring range (**Fig. 2D**).

**Correlation between Anti-Xa and aPTT in COVID-19 Patients**

We next compared the anti-Xa activity with the aPTT-CS and with the aPTT-STA for each patient separately. **Fig. 3A** shows these correlations for the anti-Xa activity and the aPTT-CS ($0.78 \leq r^2 \leq 0.94$). However, the slope of each line varies, suggesting that the association between anti-Xa and...
the aPTT varies for each individual. When comparing the aPTT-STA with the anti-Xa activity, the observed correlation ($0.34 \leq r^2 \leq 0.81$) was lower compared with the aPTT-CS, but the patient-specific slope remains (►Fig. 3B).

Correlation without taking dependence between data of all datapoints into account was lower for both the aPTT-CS ($r^2 = 0.66$, ►Fig. 3C) and the aPTT-STA ($r^2 = 0.36$, ►Fig. 3D). No samples fall within the HTR of both aPTT (50–80s) and anti-Xa (0.3–0.7 IU/mL) when using the aPTT-CS, and only eight samples fall within the HTR of both tests when using the aPTT-STA. When an anti-Xa activity of 0.3 to 0.7 IU/mL would be used as target range, the corresponding aPTT target range would equal 24.5 to 45.6 seconds using the aPTT-CS and 13.8 to 63.8 seconds using the aPTT-STA in this population.

Acute Phase Reactants Do Not Contribute to Differences in aPTT
Lastly, the relation of FVIII, fibrinogen, ATIII, thrombocytes, CRP, and ferritin was assessed with the aPTT-CS. Acute phase reactants were high: mean FVIII 606% (ref. 50–150%), mean fibrinogen 7.5 g/L (ref. 1.7–4.0 g/L), mean CRP 164 mg/L (<10 mg/L), mean ferritin 2072 µg/L (ref. 30–400 µg/L), and mean platelets 340 $\times$ 10$^9$ /L (ref. 150–350 $\times$ 10$^9$ /L) among all samples analyzed. ATIII was >70% for all patients, except patient 5 (66% and 55% in 2 samples). Mean D-dimer concentration was >7210 µg/L (ref. <500 µg/L), but is likely higher because the majority of samples had D-dimer concentrations above the measurement limit. No relevant correlation was found with the aPTT and any of them (data not shown).
In this pilot study, we explored the usefulness of two often-used aPTT assays and a chromogenic anti-Xa assay on the monitoring of UFH in seven COVID-19 patients on CRRT or ECMO. We show that these patients required a high dosage of UFH, confirming heparin resistance (defined as >35,000 IU UFH per day) in all of them. One of our patients developed bleeding during the treatment requiring the transfusion of six packed cells over the course of several days (patient 2). Another patient developed thrombosis despite high dosage of UFH (patient 3). We next showed that it is possible to measure the anti-Xa activity of UFH using an LMWH calibration and multiplication by a factor 1.55. The thusly obtained anti-Xa activity has an excellent correlation with the aPTT as measured by the Sysmex CS2100i but has a patient-specific association, indicating that patient-specific factors contribute to the relation between anti-Xa and the aPTT. Compared

Discussion

Fig. 1 (continued)
with the Sysmex CS, a significantly lower correlation was found between the anti-Xa activity and the aPTT on the Stago STA-R Max2. Lastly, we found no significant relation between FVIII, fibrinogen, thrombocytes, CRP, ferritin, or ATIII activity and the aPTT.

Because of the high incidence of coagulopathy in patients with SARS-CoV-2 infections, the International Society of Thrombosis and Haemostasis (ISTH) recommends prophylactic treatment with LMWH for all patients who require hospital admission for COVID-19.

Despite the use of standard thrombotic prophylaxis with LMWH, the cumulative incidence of thrombotic complications in COVID-19 patients admitted to the ICU is estimated to be 26, 47, and 59% over a period of 7, 14, and 21 days, respectively.\(^\text{26-28}\) White et al recently discovered that the anti-Xa recovery after spiking plasma samples with LMWH is reduced in COVID-19 plasma versus reference plasma, suggesting that a plasma factor is eliminating the LMWH.\(^\text{29}\) Similarly, Dutt et al found that the anti-Xa activity is reduced in COVID-19 patients receiving standard prophylactic dosage of LMWH.\(^\text{30}\) Pending the results of randomized controlled trials investigating the optimal dose of LMWH, local guidelines in the Netherlands advocate doubling of the prophylactic LMWH dose in patients on the ICU except in those with an increased bleeding tendency or severe renal insufficiency.

With regard to therapeutic UFH, the dosage can be adjusted based on the aPTT or the anti-Xa, with the aPTT being the measure of choice in many centers.\(^\text{10}\) The anti-Xa test is believed by many to be superior to the aPTT because it achieves therapeutic anticoagulation more rapidly, maintains the values within the therapeutic window for a longer period of time, and thus requires fewer adjustments in dosage and testing.\(^\text{31-33}\) The overall concordance between the aPTT and the anti-Xa test is low: 51.8% in adults, and dependent on age.\(^\text{34}\) Interestingly, Arachchilage et al show that age is a discriminating factor and that infants have a high aPTT versus adults that have a lower aPTT in relation to their anti-Xa levels, possibly explaining the patient-specific association we observed.\(^\text{34}\) However, the anti-Xa test only measures the anti-Xa activity of heparin, while UFH also inhibits thrombin and other coagulation factors, and it ignores all other factors that may modulate its effect in vivo. An example of such an effect is the binding of FVIII and acute phase proteins to UFH, resulting in a discordancy between aPTT and anti-Xa.\(^\text{35}\) Increased plasma concentrations of fibrinogen or FVIII may lead to aPTT shortening in 16% of patients with COVID-19.\(^\text{36}\) We believe that in such cases, the aPTT may be a more representative test to assess the net effect of heparin on the in vivo coagulation and may therefore be superior to the anti-Xa. Uprichard et al tested
this hypothesis and found that the aPTT, and not the anti-Xa, concurred with thromboelastographic and thrombin generation parameters, suggesting that apparent heparin resistance may actually be a genuine one.37

In COVID-19 patients admitted to the ICU and treated with UFH, a severe acute phase response is present. CRP, ferritin, FVIII, fibrinogen, and D-dimer levels are extremely high as also observed in the current study. Platelet count is typically normal in these patients while lymphocyte count is reduced.38 Patients in our subcohort may be more severely ill than those in other studies based on the severity of the acute phase response and the fact that CRRT or ECMO is required. This acute phase response is likely responsible for the high rate of heparin resistance in our patients as decreased ATIII, the most common cause of heparin resistance was not observed. Moreover, normal thrombocyte count in these patients may reflect a balance between increased platelet production and consumption. In severe COVID-19 patients, platelets are activated44 and may release content from their granules and thereby reduce the effect of heparin in vivo. Measuring of heparin cofactor 2 or platelet factor 4 may therefore be of interest in the future. Another hypothesis for the high need of UFH in these patients is heparanase activity. Heparanase is a heparan sulfate degrading enzyme, which also has affinity for UFH.45 Heparanase activity seems to be increased during inflammatory disease including sepsis-associated lung injury or bacterial and viral infection.46 Evidence for increased heparanase expression in COVID-19 is lacking, but based on its ability to cleave UFH it could be involved in the ethology of heparin

Fig. 2 (A) Correlation of the anti-Xa assay with the unfractionated heparin (UFH) and the low-molecular-weight heparin (LMWH) calibration. The two red samples are internal quality control samples for the UFH calibration. (B) Bland-Altman plot of the relative difference between the UFH and LMWH calibrations versus the average aXa activity. (C) Correlation of the activated partial thromboplastin time (aPTT) as measured with the mechanical (aPTT-STA) versus the optical (aPTT-CS) method. (D) Bland–Altman plot of the relative difference between the aPTT-STA and aPTT-CS versus the average aPTT. Bland–Altman plots show the relative bias (thick lines) and the 95% limit of agreement (dashed lines).
resistance in COVID-19 and may also be a potential target for further research.

When we would have used the anti-Xa activity of 0.3 to 0.7 IU/mL instead of the aPTT ratio as a basis for the HTR in this population, it would have resulted in a HTR of 24.5 to 45.6 seconds when using the Sysmex CS2100i, or a HTR of 13.8 to 63.8 seconds when using the Stago STA-R Max2. This also suggests that using only the anti-Xa assay without the aPTT may have resulted in an underdosage of heparin in our patients. At the same time, it highlights the underlying problem of poorly standardized aPTT assays. Depending on the aPTT measuring principle in combination with the reagents used, the dosage of UFH can be significantly different between hospitals. Even though both our aPTT assays have similar reference intervals and thus an identical HTR, we see poor agreement between these two assays in this population, even leading to dosage changes in two of our patients when the aPTT was measured with a different assay. Monitoring of UFH in these two patients was switched to the aPTT-STA because a biphasic waveform was detected on the aPTT-CS. These biphasic waveforms occur frequently in critically ill patients on the ICU and are caused by the formation of a precipitate of CRP and very-low-density lipoprotein after the recalcification of plasma. In COVID-19, high CRP concentrations and disseminated intravascular coagulation may cause these biphasic waveforms in optical aPTT analyzers. An interesting idea for further research would be to switch reagents between the two analyzers and to study the effect on the measured aPTT and the amount of biwaves observed.

Another point of attention is the method of anti-Xa measurement. In our laboratory, we have chosen to dilute the patient sample 1:1 with reference pool plasma, thereby supplementing ATIII. Since ATIII levels were normal in this subcohort, the difference was negligible. However, other laboratories may choose to dilute with NaCl, making this an important factor to keep in mind when interpreting laboratory parameters. All of this combined leads us to believe that it may be a mistake to forego the measuring of the aPTT in COVID-19 patients, as suggested by some colleagues. The aPTT reflects the net effect of heparin on the intrinsic coagulation cascade and therefore provides more complete information than merely anti-Xa activity. No study...
has yet to show a clear benefit of either approach and we don’t know which is better. We therefore believe that both the aPTT and the anti-Xa tests must be interpreted together, and in relation to the clinical status of the individual patients (bleeding or prothrombotic phenotype), to make the best dosage decisions. Physicians should consider to adjust the UFH dose if the HTR is not reached based on the individual patient’s situation.

Our study has several limitations. Our sample size is small and underpowered for clinically relevant endpoints. The patient population is very coherent with the same underlying disease, making it possible for significant observations with smaller sample sizes but possibly decreasing generalizability. Not every aPTT is mirrored with an aXa measurement; however, the observations in this study are consistent across the sample. For the comparison of the two aPTT assays, samples that were measured on the STA-R Max2 consisted of PFP that underwent 1 freeze-thaw cycle, while the samples measured on the CS2100i were fresh samples. Furthermore, no COVID-19 patients were treated with UFH in the absence of CVVH or ECMO, nor did we have access to comparable data of COVID-negative patients on CVVH or ECMO that could be used as a control.

Neither the aPTT nor the anti-Xa assays are perfect tests. The goal of heparinization is to decrease thrombotic events without causing bleeding. Future research should be focused around thrombin generation\(^4\) and viscoelastic testing\(^5\) in whole blood to provide an even better understanding of all the intricacies at play in COVID-19 patients.

Conflict of Interest

R.L. reports grants from Medtronic, LivaNova, Eurosets, and PulsecaTh; H.T.C. reports grants from Bayer and Pfizer, consultancy at Alveron and is a shareholder of CoagulaTh; H.T.C. reports grants from Bayer and P. elezzer, R.L. reports grants from Medtronic, LivaNova, Eurosets, and PulsecaTh; H.T.C. reports grants from Bayer and Pfizer, consultancy at Alveron and is a shareholder of CoagulaTh; H.T.C. reports grants from Bayer and P.

References

1 Pravda NS, Pravda MS, Kornowski R, Orvin K. Extracorporeal membrane oxygenation therapy in the COVID-19 pandemic. Future Cardiol 2020
2 Smerek J, Puslecki M, Ruettzler K, et al. Extracorporeal membrane oxygenation in COVID-19. Cardiol J 2020;27(02):216–217
3 Jacobs JP, Stammers AH, St Louis J, et al. Extracorporeal membrane oxygenation in the treatment of severe pulmonary and cardiac compromise in COVID-19: experience with 32 patients. ASAIOJ 2020
4 Ziants NP, Pankowsky DA, Tierney BP, Ratnoff OD, Anderson JM. Adsorption of Hageman factor (factor XII) and other human plasma proteins to biomedical polymers. J Lab Clin Med 1990;116(05):687–696
5 Despotis GJ, Avidan MS, Hogue CW Jr. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 2001;72(05):S1821–S1831
6 Tsujimoto H, Tsujimoto Y, Nakata Y, et al. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database Syst Rev 2020;3:CD012467
7 Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost 2020;18(07):1559–1561
8 Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020;18(07):1747–1751
9 Mulder M, Fawzy I, Lance M. ECMO and anticoagulation: a comprehensive review. Neth J Crit Care 2018;26(01):6–13
10 Protti A, Iapičino GE, Di Nardo M, Panigada M, Gattinoni L. Anticoagulation management and antithrombin supplementation practice during veno-venous extracorporeal membrane oxygenation: a worldwide survey. Anesthesiology 2020;132(03):562–570
11 Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsky AK. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis 2016;41(01):165–186
12 García DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(02):e24S–e43S
13 Baglin T, Barrowcliffe TW, Cohen A, Greaves MB. British Committee for Standards in Haematology. Guidelines on the use and monitoring of heparin. Br J Haematol 2006;133(01):19–34
14 Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287(07):324–327
15 Bates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med 2001;161(03):385–391
16 Marlar RA, Clement B, Gausman J. Activated partial thromboplastin time monitoring of unfractionated heparin therapy: issues and recommendations. Semin Thromb Hemost 2017;43(03):253–260
17 Marlar RA, Gausman JN. The effect of instrumentation and laboratory site on the accuracy of the APTT-based heparin therapeutic range. Int J Lab Hematol 2012;34(06):614–620
18 Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154(01):49–56
19 Thota R, Ganti AK, Subbiah S. Apparent heparin resistance in a patient with infective endocarditis secondary to elevated factor VIII levels. J Thromb Thrombolysis 2012;34(01):132–134
20 Downie I, Liederman Z, Thiyagarajah K, Selby R, Lin Y. Pseudo heparin resistance caused by elevated factor VIII in a critically ill patient. Can J Anaesth 2019;66(08):995–996
21 Durrani J, Malik F, Ali N, Jafri SIM. To be or not to be a case of heparin resistance. J Community Hosp Intern Med Perspect 2018;8(03):145–148
22 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18(04):844–847
23 Tas J, van Gessel RJ, Heines SJH, et al. Serial measurements in COVID-19-induced acute respiratory disease to unravel heterogeneity of the disease course: design of the Maastricht Intensive Care COVID cohort (MaastrichtCoh). BMJ Open 2020;10:e040175. doi: 10.1136/bmjopen-2020-040175
24 Wang Y, Kang H, Liu X, Tong Z. Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak. J Med Virol 2020;92(06):538–539
25 Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020;18(05):1023–1026
26 Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020;18(08):1995–2002
Monitoring of Unfractionated Heparin in Severe COVID-19  Streng et al.  e375

27 Klok FA, Kruij M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020

28 Klok FA, Kruij MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res 2020;191:148–150

29 White D, MacDonald S, Bull T, et al. Heparin resistance in COVID-19 patients in the intensive care unit. J Thromb Thrombolysis 2020;50(02):287–291

30 Dutt T, Simcox D, Downey C, et al. Thromboprophylaxis in COVID-19: anti-FXa—the missing factor? Am J Respir Crit Care Med 2020;202(03):455–457

31 Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zunberg MS. Activated partial thromboplastin time versus anti-factor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother 2011;45(7-8):861–868

32 Samuel S, Allison TA, Sharaf S, et al. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study. J Clin Pharm Ther 2016;41(05):499–502

33 Mitsuguro M, Okamoto A, Shironouchi Y, et al. Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin. Int J Hematol 2015;101(02):119–125

34 Arachclillage DRJ, Kamani F, Deplano S, Banya W, Laflan M. Should we abandon the APTT for monitoring unfractionated heparin? Thromb Res 2017;157:157–161

35 van Roessel S, Middeldorp S, Cheung YW, Zwinderman AH, de Pont AC. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin. Neth J Med 2014;72(06):305–310

36 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507–513

37 Uprichard J, Manning RA, Laflan MA. Monitoring heparin anticoagulation in the acute phase response. Br J Haematol 2010;149(04):613–619

38 Guan WJ, Ni ZY, Hu YChina Medical Treatment Expert Group for Covid-19, et al.; . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708–1720

39 Jenkins PV, Rawley O, Smith OP, O’Donnell JS. Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol 2012;157(06):653–663

40 Payne AB, Miller CH, Hooper WC, Lally C, Austin HD. High factor VIII, von Willebrand factor, and fibrinogen levels and risk of venous thromboembolism in blacks and whites. Ethn Dis 2014;24(02):169–174

41 Rietveld IM, Lijfering WM, le Cessie S, et al. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor. J Thromb Haemost 2019;17(01):99–109

42 Ryan K, O’Donnell JS. Elevated plasma factor VIII levels in patients with venous thrombosis—constitutional risk factor or secondary epiphenomenon? Thromb Res 2012;129(02):105–106

43 Desborough MJR, Doyle AJ, Griffiths A, Retter A, Breen KA, Hunt BJ. Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom. Thromb Res 2020;193:1–4

44 Barrett TJ, Lee A, Xia Y, et al. Biomarkers of platelet activity and vascular health associate with thrombosis and mortality in patients with COVID-19. Circ Res 2020

45 Cassinelli G, Torri G, Naggi A. Non-anticoagulant heparins as heparanase inhibitors. Adv Exp Med Biol 2020;1221:493–522

46 Sanderson RD, Elkin M, Rapraeger AC, Ilan N, Vlodavsky I. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy. FEBS J 2017;284(01):42–55

47 Toh CH, Samis J, Downey C, et al. Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca (++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood 2002;100(07):2522–2529

48 Beun R, Kusadasi N, Sikma M, Westerink J, Huisman A. Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2. Int J Lab Hematol 2020;42(Suppl 1):19–20

49 Chlebowski MM, Baltagi S, Carlson M, Levy JH, Spinella PC. Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO. Crit Care 2020;24(01):19

50 Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020;18(07):1738–1742